ASN Publications and Edgar V. Lerma highlight that atrasentan produced a clinically meaningful reduction in proteinuria in adults with IgA nephropathy already treated with RAS inhibitors and SGLT2 inhibitors.
Atrasentan provided a clinically meaningful reduction in proteinuria in adults with IgA nephropathy and proteinuria ≥0.5 g/day treated with RASi and SGLT2i therapy.
Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy #IgAN Receiving Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i)
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare